SOURCE: Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP

September 05, 2014 21:00 ET

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Prosensa Holding N.V. (RNA) to Contact the Firm

NEW YORK, NY--(Marketwired - September 05, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Prosensa Holding N.V. ("Prosensa" or the "Company") (NASDAQ: RNA) of the September 16, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Prosensa, certain executives and underwriters of the Company's initial public offering ("IPO").

A complaint has been filed in the Southern District of New York on behalf of all persons who purchased or otherwise acquired Prosensa ordinary shares pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the "Registration Statement") issued in connection with the IPO on or about June 28, 2013 (the "Class Period").

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that the Registration Statement contained materially false and/or misleading statements and/or omitted material information concerning the development status of drisapersen (Prosensa's first and lead product candidate), drisapersen's Phase II and Phase III clinical studies, and the prospects for regulatory approval of drisapersen.

On September 20, 2013, the Company announced in a joint press release with GlaxoSmithKline, that drisapersen did not meet the primary endpoint in the Phase III study.

Following this news, the price of Prosensa stock declined by $16.86, or over 70%, to close at $7.14 on September 20, 2013.

Request more information now by clicking here: www.faruqilaw.com/RNA. There is no cost or obligation to you.

Take Action

If you invested in Prosensa securities pursuant and/or traceable to the Registration Statement issued in connection with the IPO on or about June 28, 2013, and would like to discuss your legal rights, visit www.faruqilaw.com/RNA. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Prosensa's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contact Information

  • FARUQI & FARUQI, LLP
    369 Lexington Avenue, 10th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    rgonnello@faruqilaw.com
    Telephone: (877) 247-4292 or (212) 983-9330